Resistance biomarkers for hdac inhibitors
作者： Torsten Bernhard Trowe
DOI:
关键词:
摘要: Provided herein are methods for identifying a cancer patient at risk resistance to an HDAC inhibitor therapy, comprising obtaining tumor sample from the patient; detecting presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in sample; quantifying level TSPYL5 sample, wherein high expression, relative defined threshold TSPYL5, correlates with therapy; and applying correlation identify therapy. Also provided is method increased likelihood positive clinical response therapy said low identifies Related compositions also provided.
lens.org参考文章(219)
Lindsay Stimson, Nicholas B. La Thangue, Biomarkers for predicting clinical responses to HDAC inhibitors Cancer Letters. ,vol. 280, pp. 177- 183 ,(2009) , 10.1016/J.CANLET.2009.03.016
James E Bradner, Nathan West, Melissa L Grachan, Edward F Greenberg, Stephen J Haggarty, Tandy Warnow, Ralph Mazitschek, Chemical phylogenetics of histone deacetylases Nature Chemical Biology. ,vol. 6, pp. 238- 243 ,(2010) , 10.1038/NCHEMBIO.313
Guillermo Garcia-Manero, Hagop M. Kantarjian, Blanca Sanchez-Gonzalez, Hui Yang, Gary Rosner, Srdan Verstovsek, Michael Rytting, William G. Wierda, Farhad Ravandi, Charles Koller, Lianchun Xiao, Stefan Faderl, Zeev Estrov, Jorge Cortes, Susan O'Brien, Elihu Estey, Carlos Bueso-Ramos, Jackie Fiorentino, Elias Jabbour, Jean-Pierre Issa, Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. ,vol. 108, pp. 3271- 3279 ,(2006) , 10.1182/BLOOD-2006-03-009142
Yuka Sasakawa, Yoshinori Naoe, Takeshi Inoue, Tatsuya Sasakawa, Masahiko Matsuo, Toshitaka Manda, Seitaro Mutoh, Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochemical Pharmacology. ,vol. 64, pp. 1079- 1090 ,(2002) , 10.1016/S0006-2952(02)01261-3
Maliha Khan, Areeba Saif, Steven Sandler, Aibek E. Mirrakhimov, Idelalisib for the Treatment of Chronic Lymphocytic Leukemia International Scholarly Research Notices. ,vol. 2014, pp. 931858- 931858 ,(2014) , 10.1155/2014/931858
Hiroshi Kosugi, Masafumi Ito, Yukiya Yamamoto, Masayuki Towatari, Mamoru Ito, Ryuzo Ueda, Hidehiko Saito, Tomoki Naoe, In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid /scid Mice Japanese Journal of Cancer Research. ,vol. 92, pp. 529- 536 ,(2001) , 10.1111/J.1349-7006.2001.TB01126.X
Angela Nebbioso, Nicole Clarke, Emilie Voltz, Emmanuelle Germain, Concetta Ambrosino, Paola Bontempo, Rosana Alvarez, Ettore M Schiavone, Felicetto Ferrara, Francesco Bresciani, Alessandro Weisz, Angel R de Lera, Hinrich Gronemeyer, Lucia Altucci, Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine. ,vol. 11, pp. 77- 84 ,(2005) , 10.1038/NM1161
Brian J. Nickoloff, Nicholas M. Dean, C. Frank Bennett, Brett P. Monia, Qingqing Zhang, Antisense modulation of bcl-x expression ,(1999)
Michael Nebozhyn, Andrey Loboda, Laszlo Kari, Alain H. Rook, Eric C. Vonderheid, Stuart Lessin, Carole Berger, Richard Edelson, Calen Nichols, Malik Yousef, Lalitha Gudipati, Meiling Shang, Michael K. Showe, Louise C. Showe, Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood. ,vol. 107, pp. 3189- 3196 ,(2006) , 10.1182/BLOOD-2005-07-2813
Stefania Scala, Nadia Akhmed, U. S. Rao, Ken Paull, Lu-Bin Lan, Bruce Dickstein, Jong-Seok Lee, Galal H. Elgemeie, Wilfred D. Stein, Susan E. Bates, P-glycoprotein substrates and antagonists cluster into two distinct groups. Molecular Pharmacology. ,vol. 51, pp. 1024- 1033 ,(1997) , 10.1124/MOL.51.6.1024